Skip to main content
main-content

Long-acting insulins

04-01-2021 | Insulin | News

Long-acting insulin analogs may lower hypoglycemia risk in older people with type 2 diabetes

Older people with type 2 diabetes who initiate treatment with long-acting insulin analogs have a lower risk for severe hypoglycemia than those using neutral protamine Hagedorn insulin, real-world study findings suggest.

03-31-2021 | Older adults | News

Glargine-300 might be preferable for older people with type 2 diabetes

Analysis of older participants in the BRIGHT trial suggests that this subgroup may do slightly better with insulin glargine-300 than with degludec.

03-24-2021 | Basal insulin Fc | News

Second weekly insulin shows phase 2 promise for type 2 diabetes

A novel weekly insulin achieves similar glycemic control to insulin degludec at a higher fasting glucose target, report the investigators at the virtual ENDO 2021 meeting.

07-03-2020 | Physical activity | News

Fructose boost may alleviate type 1 diabetes exercise-induced hypoglycemia risk

Consuming a single shot of fructose prior to exercise is a feasible strategy to reduce the risk for exercise-induced hypoglycemia among men with type 1 diabetes treated with insulin degludec, suggest findings from a proof-of-concept study.

06-17-2020 | ADA 2020 | Conference coverage | News

​​​​​​​Support for insulin degludec use in type 1 diabetes patients prone to nocturnal hypoglycemia

Findings from the HypoDeg trial suggest that insulin degludec is associated with a lower risk for hypoglycemia than insulin glargine U100 among people with type 1 diabetes who are prone to nocturnal severe hypoglycemia.

06-16-2020 | ADA 2020 | Conference coverage | News

First weekly insulin shows equivalence with glargine in type 2 diabetes

A novel insulin that can be given as a once-weekly injection has achieved promising results in a randomized phase 2 trial involving people with type 2 diabetes.

05-27-2020 | Insulin glargine | News

Second- and first-generation insulin analogs offer similar pediatric type 1 diabetes benefits

Findings from the EDITION JUNIOR trial indicate that glargine-300 and glargine-100 have similar efficacy and safety when used with mealtime insulin in children and adolescents with type 1 diabetes.

04-17-2020 | Insulin glargine | News

Similar glycemic control with glargine U300, U100 for inpatients with type 2 diabetes

Hospitalized people with poorly controlled type 2 diabetes who are treated with insulin glargine U300 have comparable glycemic control to those given the U100 formulation, and may have a lower risk for hypoglycemia, researchers report.

Related topics

Superior

Related

Specific

Image Credits